Why the study?
Real-world evidence comparing effectiveness, safety, and cost outcomes of oral anticoagulants in NVAF patients with coronary or peripheral artery disease was limited.
Does apixaban reduce the risk of stroke/systemic embolism, major bleeding, and healthcare costs compared to warfarin, dabigatran, or rivaroxaban in older NVAF patients with CAD and/or PAD?
Does apixaban reduce the risk of stroke/systemic embolism, major bleeding, and healthcare costs compared to warfarin, dabigatran, or rivaroxaban in older NVAF patients with CAD and/or PAD?
Answers are grounded in this paper and cite their sources.
In older NVAF patients with CAD or PAD, apixaban is associated with lower risks of stroke/systemic embolism, major bleeding, and related healthcare costs compared to warfarin, dabigatran, and rivaroxaban.
To address literature gaps on treatment with real-world evidence, this study compared effectiveness, safety, and cost outcomes in NVAF patients with coronary or peripheral artery disease (CAD, PAD) prescribed apixaban versus other oral anticoagulants. NVAF patients aged ≥65 years co-diagnosed with CAD/PAD initiating warfarin, apixaban, dabigatran, or rivaroxaban were selected from the US Medicare population (January 1, 2013 to September 30, 2015). Propensity score matching was used to match apixaban versus warfarin, dabigatran, and rivaroxaban cohorts. Cox models were used to evaluate the risk of stroke/systemic embolism (SE), major bleeding (MB), all-cause mortality, and a composite of stroke/myocardial infarction/all-cause mortality. Generalized linear and two-part models were used to compare stroke/SE, MB, and all-cause costs between cohorts. A total of 33,269 warfarin-apixaban, 9,335 dabigatran-apixaban, and 33,633 rivaroxaban-apixaban pairs were identified after matching. Compared with apixaban, stroke/SE risk was higher in warfarin (hazard ratio [HR]: 1.93; 95% confidence interval [CI]: 1.61 to 2.31), dabigatran (HR: 1.69; 95% CI: 1.18 to 2.43), and rivaroxaban (HR: 1.24; 95% CI: 1.01 to 1.51) patients. MB risk was higher in warfarin (HR: 1.67; 95% CI: 1.52 to 1.83), dabigatran (HR: 1.37; 95% CI: 1.13 to 1.68), and rivaroxaban (HR: 1.87; 95% CI: 1.71 to 2.05) patients vs apixaban. Stroke/SE- and MB-related medical costs per-patient per-month were higher in warfarin, dabigatran, and rivaroxaban patients versus apixaban. Total all-cause health care costs were higher in warfarin and rivaroxaban patients compared with apixaban patients. In conclusion, compared with apixaban, patients on dabigatran, rivaroxaban, or warfarin had a higher risk of stroke/SE, MB, and event-related costs.
No takes yet. Share an insight, caveat, or question.
Lópes et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: